We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+39.96%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.39B
AUM Growth
+$491M
Cap. Flow
-$128M
Cap. Flow %
-3.78%
Top 10 Hldgs %
67.91%
Holding
89
New
9
Increased
10
Reduced
15
Closed
13

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$99.2M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$75.1M
3
GOSS icon
Gossamer Bio
GOSS
+$51.6M
4
KYMR icon
Kymera Therapeutics
KYMR
+$21M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$13.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$118M
2
RVMD icon
Revolution Medicines
RVMD
+$54.4M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$53.7M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$43.5M
5
ARGX icon
argenx
ARGX
+$39.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.27%
2 Financials 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRZNW icon
76
Surrozen Inc Warrant
SRZNW
$75.6K
$135K ﹤0.01%
66,665
– –
ADVM
77
DELISTED
Adverum Biotechnologies
ADVM
– –
-104,670
Closed -$1.26M
BOLT icon
78
Bolt Biotherapeutics
BOLT
$7.72M
– –
-7,500
Closed -$306K
CLDX icon
79
PUT
Celldex Therapeutics
CLDX
$2.79B
– –
-115,200
Closed -$3.11M
DYN icon
80
Dyne Therapeutics
DYN
$4.28B
– –
-215,000
Closed -$1.48M
EXEL icon
81
CALL
Exelixis
EXEL
$14.2B
– –
-760,000
Closed -$15.8M
INCY icon
82
Incyte
INCY
$26B
– –
-182,783
Closed -$13.9M
MRSN
83
DELISTED
Mersana Therapeutics
MRSN
– –
-12,438
Closed -$1.44M
OLMA icon
84
Olema Pharmaceuticals
OLMA
$1.01B
– –
-353,701
Closed -$1.44M
SPRY icon
85
ARS Pharmaceuticals
SPRY
$563M
– –
-575,359
Closed -$2.44M
VERV
86
DELISTED
Verve Therapeutics
VERV
– –
-98,593
Closed -$1.51M
CERE
87
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-1,646,260
Closed -$43.5M
PRDS
88
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
– –
-200,000
Closed -$614K
EVLO
89
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
– –
-10,021
Closed -$423K
1 2 3
4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q3 2022 Portfolio in Review

As of Q3 2022, EcoR1 Capital held 89 positions worth $3.39B, up 17% from $2.9B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital withdrew a net $128M in Q3 2022, closing 13 positions and reducing 15 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $43.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

Against the trend, EcoR1 Capital opened a new position in SpringWorks Therapeutics worth $98.7M.

  • EcoR1 Capital's largest Q3 2022 buy was SpringWorks Therapeutics: 3,460,208 shares worth $98.7M.
  • EcoR1 Capital added most to Centessa Pharmaceuticals in Q3 2022, an estimated $13.5M increase.
  • EcoR1 Capital's biggest Q3 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $118M.
  • EcoR1 Capital fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2022, selling an estimated $43.5M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $3.39B portfolio in Q3 2022.
  • EcoR1 Capital opened 9 new positions and closed 13 in Q3 2022.
  • EcoR1 Capital's portfolio value rose 17% quarter-over-quarter to $3.39B.

Based on EcoR1 Capital's 13F filing for Q3 2022, filed 14 Nov 2022.